Vesicare (solifenacin) / Astellas - LARVOL DELTA

Is urinary myelin basic protein the key to understanding the role of vitamin D supplementation in paediatric overactive bladder-dry? Results from a three-stage clinical investigation. (PubMed, BJU Int) - "Urinary MBP serves as a predictive biomarker for a distinct 'neuro-vulnerable' paediatric OAB-dry subtype, characterised by 25(OH)D levels of <35 ng/mL. These findings position uMBP as a potential tool for precision treatment stratification and suggest that paediatric OAB may represent a sentinel sign of underlying neural axis vulnerability associated with low vitamin D status."

Journal • Overactive Bladder • Pediatrics • MBP

Rational Design of a Carbonyl Reductase Yields a Robust Biocatalyst for Industrial Synthesis of (R)-3-Quinuclidinol. (PubMed, Biotechnol J) - "(R)-3-quinuclidinol is a pivotal chiral synthon for pharmaceuticals such as talsaclidine, revatropate, and solifenacin...Furthermore, the V167F/C171Y variant was applied in a 50-L bioreactor, wherein only 7.50 g/L DCW (dry cell weight) of whole-cell biocatalyst was required to completely convert 100 g/L substrate within 6 h, affording (R)-3-quinuclidinol with >99% conversion and enantiomeric excess (ee). The exceptional biocatalytic performance, coupled with high substrate tolerance and operational stability, underscores the potential of this engineered enzyme for sustainable industrial manufacturing."

Journal

Efficacy of Solifenacin Combined with Biofeedback in Children with Neurogenic Detrusor Overactivity Caused by Primary Tethered Cord Syndrome. (PubMed, J Child Neurol) - "Despite these superior outcomes, group B required lower cumulative doses of solifenacin than group A. Additionally, no statistically significant improvements were found in PVRU or detrusor function during voiding in either group throughout the follow-up period.ConclusionsThe combination of solifenacin and biofeedback proved to be an effective treatment for pediatric NDO caused by primary TCS, compared with solifenacin monotherapy. This combined approach not only enhanced clinical outcomes but also allowed for reduced solifenacin dosages."

Journal • Overactive Bladder • Pediatrics

Low-intensity Shockwave Therapy Versus Solifenacin for the Treatment of Overactive Bladder in Women (clinicaltrials.gov) - P4 | N=70 | Recruiting | Sponsor: Mansoura University

New P4 trial • Overactive Bladder • Urinary Incontinence

Validated comprehensive RP HPLC approach for separation and quantification of solifenacin and mirabegron in the presence of their degradation products. (PubMed, Sci Rep) - No abstract available

Journal

Comparative Analysis of Solifenacin Plus Desmopressin Versus Desmopressin Alone in the Treatment of Primary Mono Symptomatic Nocturnal Enuresis (AUA 2026) - No abstract available

Urinary Incontinence

Comparative Efficacy of Mirabegron, Propiverine, and Solifenacin Versus Placebo in BCG-Induced Lower Urinary Tract Symptoms: A Prospective Randomized Placebo-Controlled Trial (AUA 2026) - No abstract available

Clinical • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • Urothelial Cancer

Phosphodiesterase inhibitors for the management of lower urinary tract symptoms in men without benign prostatic hyperplasia: a systematic review. (PubMed, Transl Androl Urol) - "Interventions included tadalafil, sildenafil, and combination regimens with tamsulosin or solifenacin. PDE5-Is, especially tadalafil, are effective and well-tolerated for non-BPH LUTS in men, offering advantages beyond urinary symptom relief, including sexual function preservation and pain reduction. These potential effects should be further explored, particularly when erectile dysfunction (ED) or discomfort is present."

Journal • Review • Benign Prostatic Hyperplasia • Erectile Dysfunction • Overactive Bladder • Pain

Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients (clinicaltrials.gov) - P2 | N=110 | Recruiting | Sponsor: University of Arkansas | Trial completion date: Sep 2027 ➔ Sep 2028 | Trial primary completion date: Jul 2026 ➔ Jul 2027

Trial completion date • Trial primary completion date • Breast Cancer • Oncology • Solid Tumor

StayDry-2023: StayDry (clinicaltrialsregister.eu) - P4 | N=216 | Active, not recruiting | Sponsor: Region Midtjylland | Recruiting ➔ Active, not recruiting

Enrollment closed • Urinary Incontinence • Urology

New drug approaches: ADC, bispec. antibody (DKK 2026) - No abstract available

Head and Neck Cancer • Oncology • Solid Tumor

Efficacy of Gabapentin Combined With Solifenacin for Non-neurogenic Overactive Bladder in Women (clinicaltrials.gov) - P3 | N=60 | Not yet recruiting | Sponsor: Mansoura University

Monotherapy • New P3 trial • Overactive Bladder

WoMEN'S: Randomized Controlled Trial Comparing Low Dose Tadalafil Versus Solifenacin For Management of Overactive Bladder in Women: Multicenter Egyptian National Study (clinicaltrials.gov) - P4 | N=480 | Recruiting | Sponsor: Mansoura University

New P4 trial • Overactive Bladder

Mirabegron in Patients With Age-Related Macular Degeneration (clinicaltrials.gov) - P=N/A | N=312 | Not yet recruiting | Sponsor: University of Naples | Initiation date: Jan 2026 ➔ Apr 2026

Trial initiation date • Age-related Macular Degeneration • Dry Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Overactive Bladder • Retinal Disorders

Clinical Observation on the Efficacy of Urethral Dilation Combined with Bladder Instillation in the Treatment of Overactive Bladder in Female Patients (ChiCTR) - P=N/A | N=100 | Completed | Sponsor: The People's Hospital of Linxia; The People's Hospital of Linxia

New trial • Overactive Bladder

Atrial fibrillation signals associated with overactive bladder drugs across JADER and FAERS: disproportionality and time-to-onset analyses. (PubMed, Front Pharmacol) - "Consistent AF signals were identified for solifenacin succinate and mirabegron, whereas other agents did not meet the prespecified criteria. These findings are hypothesis-generating, given the limitations of SRSs, such as underreporting, missing dates, and unknown exposure-and they reflect reporting patterns rather than causal risk. They outline strata and early treatment periods that may warrant clinical attention and help prioritize pharmacovigilance and targeted hypothesis-driven evaluation in routine OAB care."

Journal • Atrial Fibrillation • Cardiovascular • Overactive Bladder

Risk Factors for Treatment Failure in Women With Detrusor Overactivity Receiving Combined Pharmacotherapy (clinicaltrials.gov) - P=N/A | N=61 | Completed | Sponsor: Mackay Memorial Hospital

New trial • Overactive Bladder

Effects of Treatment and Weather Variables on Nocturnal Enuresis: Long-Term Analysis Using the Classification and Regression Trees Model. (PubMed, Cureus) - "Our findings suggest that effective long-term management of NE may require individualized treatment plans that account for clinical and weather-related variables. Among weather-related variables, consideration of seasonal and environmental factors may be especially important in managing NE."

Journal • Pediatrics • Urinary Incontinence

Efficacy and Safety of Mirabegron Versus Solifenacin in the Treatment of Overactive Bladder in Children: A Systematic Review and Meta-Analysis (EAU 2026) - No abstract available

Retrospective data • Review • Overactive Bladder

Solifenacin Plus Tadalafil vs Solifenacin Alone for Overactive Bladder in Females (clinicaltrials.gov) - P=N/A | N=80 | Completed | Sponsor: Ain Shams University

New trial • Overactive Bladder

Mirabegron in Patients With Age-Related Macular Degeneration (clinicaltrials.gov) - P3 | N=312 | Not yet recruiting | Sponsor: University of Naples

New P3 trial • Age-related Macular Degeneration • Dry Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Overactive Bladder • Retinal Disorders

Case Report: Double Trouble: Solifenacin and Fluoxetine's Unexpected QT Prolongation Synergy (ASHP 2025) - No abstract available

Case report • Clinical

Peroneal electric transcutaneous neuromodulation versus solifenacin in the treatment of the overactive bladder wet. (PubMed, Cent European J Urol) - "Both treatments led to significant and similar improvements in all bladder diary variables, OAB V8 score, and QoL. The results of this secondary analysis confirm that peroneal eTNM® has significantly better safety profile and comparable efficacy versus solifenacin in the subgroup of incontinent OAB patients."

Journal • Overactive Bladder

Deprescribing dRrugs for Overactive Bladder in General Practice (DROP) (clinicaltrials.gov) - P=N/A | N=72 | Active, not recruiting | Sponsor: Anne Estrup Olesen | Recruiting ➔ Active, not recruiting

Enrollment closed • Overactive Bladder

Efficacy and Mechanism of High-Dose Vitamin D Supplementation in Pediatric OAB-Dry: A Randomized Clinical Trial Integrating Urinary Myelin Basic Protein as a Theranostic Biomarker (clinicaltrials.gov) - P=N/A | N=180 | Completed | Sponsor: Xing Liu | Recruiting ➔ Completed

Biomarker • Trial completion • Overactive Bladder • Pediatrics